Hims & Hers Health (NYSE:HIMS) Hits New 1-Year Low – Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price hit a new 52-week low during trading on Thursday . The stock traded as low as $15.46 and last traded at $16.4940, with a volume of 4912810 shares changing hands. The stock had previously closed at $15.84.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers agreed to buy Australian digital-telehealth leader Eucalyptus in a transaction valued at about $1.15 billion, giving HIMS immediate international scale and a foothold in Australia — a clear growth signal that likely underpins the stock’s uptick. Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider
• Neutral Sentiment: Company press release frames the deal as accelerating HIMS’ vision to be a global consumer-health platform; strategic rationale is expansion of personalized-care offerings, but the acquisition adds integration and execution risk. Hims & Hers Announces Agreement to Acquire Eucalyptus
• Neutral Sentiment: Analyst and market commentary is mixed: some note HIMS is oversold with upside potential based on long-term telecom/sexual-wellness trends, while others have trimmed price targets after recent execution and regulatory noise — this creates near-term volatility but also sets up a possible recovery narrative if integration and results meet expectations. Analyst coverage and price-target commentary
• Negative Sentiment: Regulatory and legal overhang persists: Hims & Hers has faced pushback over its GLP‑1/weight-loss play — including scrutiny from regulators and a high-profile lawsuit from Novo Nordisk — which increases litigation risk and could constrain that growth pivot. Hims & Hers GLP-1 pill gambit backfires
• Negative Sentiment: Shareholder litigation risk: a law firm announced an investigation into whether HIMS made misleading disclosures, which could lead to additional legal costs or settlements. This amplifies investor uncertainty even as the company pursues M&A. Schall Law Firm investigation notice

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HIMS shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Hims & Hers Health and gave the stock a “hold” rating in a research report on Tuesday, February 10th. TD Cowen dropped their target price on shares of Hims & Hers Health from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Monday, February 9th. BTIG Research decreased their price target on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $39.32.

Hims & Hers Health Price Performance

The firm’s 50 day simple moving average is $29.50 and its two-hundred day simple moving average is $40.96. The firm has a market capitalization of $3.61 billion, a P/E ratio of 29.41, a P/E/G ratio of 3.04 and a beta of 2.43. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health announced that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to purchase up to 3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 82,963 shares of company stock worth $2,944,621. 13.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Quent Capital LLC bought a new position in Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Binnacle Investments Inc bought a new stake in Hims & Hers Health in the third quarter valued at $28,000. Virtus Advisers LLC purchased a new position in Hims & Hers Health during the 2nd quarter valued at $26,000. Quaker Wealth Management LLC bought a new position in Hims & Hers Health in the 2nd quarter worth $29,000. Finally, Bessemer Group Inc. lifted its position in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.